Respiratory Infections

The new pathogen panel will distinguish between 20 different common and serious respiratory infections, giving clinicians more confidence in flu season diagnoses.

A pair of investigative monoclonal antibodies from Lilly show promise for mitigating mild to moderate COVID-19 risks of escalation.

Fauci also shares suggestions for college campus to mitigate community-based spread while classes continue.

The President's hospital stay continues through a third day, with conflicting messages on his health and an escalation in therapy.

A discussion with an expert on the particularities of the vaccines, which vary in temperature climate requirements and dosages.

A collection of perspectives on how the virus is affecting patients outside of infectious disease.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.

New CDC data showed adults aged 20-29 made up more than 20% of all confirmed cases from June-August of this year.

Brad Spellberg, MD, emphasizes his belief the Affordable Care Act needs to be retained so as long as the pandemic persists.

International collaboration, fast action, and mRNA platform technology led to phase 3 trials in record time—without compromise of safety standards.

The agency requested data this week, following the pause of large-scale international assessment after a non-fatal serious adverse event was reported in a UK participant earlier this month.

The country is split on certain strategies and a potential vaccine. Here's why the message needs to go from national to regional.

The test provides qualitative detection of nucleic acid from SARS-CoV-2 in oral saline rinse specimens, nasopharyngeal swab, and nasal swab specimens in a universal transport media, as well as nasal swabs collected in oral saline rinse.

Brad Spellberg, MD, describes the inconsistent, impersonal messaging given to the public as cases begin to rise again.

From acute kidney injury to children with ADHD, here's the latest research and discussions around the pandemic's effect on other specialties.

Stanford investigators suggest the findings could continually represent an accurate estimate of US antibody accrual.

An interview with a Harvard-based researcher on troubling associations between RDW and hospitalized COVID-19 patients' mortality risks.

New international analysis highlights successes—and shortcomings—among Pacific Asia and European regions who began to reopen their societies.

The EUA grants clinicians and caregivers capability to provide serologic assay results in person to potentially infected patients.

Is it still safe to take your child to get a vaccine during the pandemic? According to experts, there are safety measures in place for this critically important task.

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

Rheumatologists are understandably concerned regarding immune suppressed patients amid the coronavirus (COVID-19) pandemic. What are the risk factors for hospitalization? And do drugs which act against inflammation complicate matters?

On Friday, new guidelines from CDC sought to show how the pandemic coronavirus (COVID-19) spreads. By Monday, those guidelines changed.

Dr. Shervin Molayem, DDS, continues our discussion on his recent paper The Mouth-COVID Connection: Il-6 Levels in Periodontal Disease — Potential Role in COVID-19-Related Respiratory Complications.

The country successfully managed thousands of mild cases among foreign construction workers at the height of the pandemic through an isolation facility. It may not be an applicable model, though.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

Do the norms of media coverage of SARS-CoV-2 worsen rising acute stress and depressive symptoms in the United States?

The guidance clarification published today comes just a day after reports a polarizing guidance was published last month without full review nor consensus from the agency.

Antibodies are just one part of the body's immune response. And growing evidence suggests many of us could already have cross-reactive cellular immunity to the “novel” coronavirus.